Gw Pharmaceuticals Plc (GWPH)

Trade GWPH now with
9/23/2020 4:00:59 AM GW Pharmaceuticals Gets Australian Therapeutic Goods Administration Approval For EPIDYOLEX
6/30/2020 7:14:46 AM GW Pharmaceuticals Announces Strategy For Bringing Nabiximols To U.S. Market
4/6/2020 9:10:27 AM GW Pharmaceuticals: EPIDIOLEX Oral Solution Has Been Descheduled And Is No Longer Controlled Substance
3/31/2020 7:17:48 AM GW Pharma: FDA Accept SNDA Filing With Priority Review For EPIDIOLEX
3/13/2020 7:06:55 AM GW Pharmaceuticals Submits Type II Variation Application To EMA To Expand Use Of EPIDYOLEX Oral Solution
3/2/2020 2:03:38 AM GW Pharmaceuticals Regains Exclusive Commercialisation Rights To Sativex In UK
2/3/2020 7:07:59 AM GW Pharma And Greenwich Biosciences Submit SNDA To FDA For Epidiolex
1/12/2020 8:04:16 PM GW Pharma Reports Q4 Total Preliminary Net Product Sales Of $108 Mln
12/5/2019 7:20:22 AM GW Pharmaceuticals To Present Variety Of Data At AES Annual Meeting
9/23/2019 7:07:05 AM GW Pharma Gets European Commission Approval For EPIDYOLEX
7/26/2019 6:39:06 AM GW Pharmaceuticals Receives Positive CHMP Opinion For EPIDYOLEX
3/18/2019 7:42:55 AM GW Research Agrees To Sell Rare Pediatric Disease Priority Review Voucher For $105 Mln
11/27/2018 4:05:19 PM GW Pharmaceuticals Q4 Loss/share $0.23 Vs. Loss $0.18 Year Ago
11/26/2018 7:03:13 AM GW Pharma Announces Second Positive Phase 3 Pivotal Trial For EPIDIOLEX Oral Solution CV For Dravet Syndrome